These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36180011)

  • 1. May a different kinetic mode explain the high efficacy/safety profile of inhaled budesonide?
    Brattsand R; Selroos O
    Pulm Pharmacol Ther; 2022 Dec; 77():102167. PubMed ID: 36180011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Versus Old: The Impact of Changing Patterns of Inhaled Corticosteroid Prescribing and Dosing Regimens in Asthma Management.
    Singh D; Garcia G; Maneechotesuwan K; Daley-Yates P; Irusen E; Aggarwal B; Boucot I; Berend N
    Adv Ther; 2022 May; 39(5):1895-1914. PubMed ID: 35284999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
    Wang MT; Lai JH; Huang YL; Liou JT; Cheng SH; Lin CW; Pan HY; Hsu YJ; Tsai CL
    Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged ≥16 years) with asthma: a sub-analysis of the COSMOS study.
    Vogelmeier C; Naya I; Ekelund J
    Clin Drug Investig; 2012 Jul; 32(7):439-49. PubMed ID: 22607479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of early effects of budesonide/formoterol maintenance and reliever therapy with fluticasone furoate/vilanterol for asthma patients requiring step-up from inhaled corticosteroid monotherapy.
    Hozawa S; Terada M; Haruta Y; Hozawa M
    Pulm Pharmacol Ther; 2016 Apr; 37():15-23. PubMed ID: 26850307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD.
    Muiser S; Imkamp K; Seigers D; Halbersma NJ; Vonk JM; Luijk BHD; Braunstahl GJ; van den Berg JW; Kroesen BJ; Kocks JWH; Heijink IH; Reddel HK; Kerstjens HAM; van den Berge M
    Thorax; 2023 May; 78(5):451-458. PubMed ID: 36725331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.
    Frois C; Wu EQ; Ray S; Colice GL
    Clin Ther; 2009 Dec; 31(12):2779-803. PubMed ID: 20110019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment persistence and exacerbations in patients with asthma initiating treatment with inhaled corticosteroids and beta-adrenergic agonists: retrospective cohort study.
    Sicras-Mainar A; Gómez Rodríguez B; Traseira-Lugilde S; Fernández-Sánchez T; Velasco Garrido JL
    BMJ Open; 2022 Apr; 12(4):e053964. PubMed ID: 35443946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the Effects of Changing Patterns of Inhaled Corticosteroid Dosing and Adherence with Fluticasone Furoate and Budesonide on Asthma Management.
    Daley-Yates P; Singh D; Igea JM; Macchia L; Verma M; Berend N; Plank M
    Adv Ther; 2023 Sep; 40(9):4042-4059. PubMed ID: 37438554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged > or =16 years with asthma: post hoc analysis of a randomized, double-blind study.
    Kuna P
    Clin Drug Investig; 2010; 30(9):565-79. PubMed ID: 20593912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effects of budesonide/formoterol maintenance and reliever therapy with fluticasone/salmeterol fixed-dose treatment on airway inflammation and small airway impairment in patients who need to step-up from inhaled corticosteroid monotherapy.
    Hozawa S; Terada M; Hozawa M
    Pulm Pharmacol Ther; 2014 Apr; 27(2):190-6. PubMed ID: 24388868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of fluticasone/formoterol with budesonide/formoterol pMDI in adults with moderate to severe persistent asthma: Results from a 12-week randomized controlled trial.
    Balki A; Balamurugan S; Bardapurkar S; Dalal S; Singh A; Singh BP; Vaidya A; Gogtay JA
    Pulm Pharmacol Ther; 2018 Feb; 48():28-36. PubMed ID: 28890299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the efficacy and safety of fluticasone propionate/formoterol fixed-dose combination.
    Kilaru SC; Bansal AG; Naik VS; Lopez M; Gogtay JA
    Expert Rev Respir Med; 2022 May; 16(5):529-540. PubMed ID: 35727177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review.
    Solidoro P; Patrucco F; Bagnasco D
    Expert Rev Respir Med; 2019 Nov; 13(11):1087-1094. PubMed ID: 31498714
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of Budesonide/formoterol versus Fluticasone furoate/vilanterol as maintenance and reliever therapy for asthma control: a real-world observational study.
    Huang WC; Cheng WC; Chen CY; Liao WC; Wu BR; Chen WC; Tu CY; Chen CH; Hsu WH
    BMC Pulm Med; 2024 Aug; 24(1):374. PubMed ID: 39085818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Safety Profile of the Fixed-Dose Combination Corticosteroid and Long-acting β
    Price DB; Carter V; Martin J; Gardener EA; Skinner D; Yang S; Hoffman M; Willis JC; Cooper AJ
    Drugs; 2020 Jan; 80(1):47-60. PubMed ID: 31749061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
    Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
    Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
    Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
    Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of COPD-related outcomes in patients initiating a once daily or twice daily ICS/LABA.
    Stanford RH; Parker ED; Reinsch TK; Buikema AR; Blauer-Peterson C
    Respir Med; 2019 Apr; 150():1-7. PubMed ID: 30961933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β
    Devillier P; Humbert M; Boye A; Zachgo W; Jacques L; Nunn C; West S; Nicholls A; Antoun Z; Spinu L; Grouin JM
    Respir Med; 2018 Aug; 141():111-120. PubMed ID: 30053956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.